FDABusinessOpenAI and the FDA Are Holding Talks About Using AI In Drug EvaluationBy Zoë Schiffer, Emily Mullin, and Will KnightBusinessElon Musk’s $1 Spending Limit Is Paralyzing Federal AgenciesBy Emily Mullin and Zoë SchifferScienceThe Ozempic Shortage Is OverBy Kate Knibbs and Emily MullinGearHere’s What the FDA Label on Your Personal Care Products MeansBy Boutayna Chokrane ScienceA Popular Decongestant Doesn’t Work. The FDA Is Finally Doing Something About ItBy Beth Mole, Ars TechnicaScienceA Major GLP-1 Drug Shortage Is Over. Some Patients Aren’t CelebratingBy Kate KnibbsScienceThe FDA Just Rejected a Bid for MDMA to Treat PTSDBy Emily MullinScienceIt’s Shockingly Easy to Buy Off-Brand Ozempic Online, Even if You Don’t Need ItBy Kate KnibbsGearSemaglutide for the PeopleBy Michael CaloreScienceThe Case for MDMA’s Approval Is Riddled With ProblemsBy Emily MullinScienceNo One Knows How Far Bird Flu Has SpreadBy Matt ReynoldsScienceA Study at the Center of the Abortion Pill Battle Was Just RetractedBy Emily MullinScienceA Cutting-Edge Cancer Treatment May Cause Cancer. The FDA Is InvestigatingBy Emily MullinGear7 Rapid At-Home Covid-19 Tests—and Where to Find ThemBy Brenda StolyarCultureAdderall Shortages Are Dragging On—Can Video Games Help?By Celia FordScienceThe First Pill for Postpartum Depression Is Almost HereBy Emily MullinScienceThe US Finally Approved an Over-the-Counter Birth Control Pill. Here’s What to KnowBy Emily MullinThe Big StoryThe Explosive Legacy of the Pandemic Hand Sanitizer BoomBy Amy MartynScienceThe US Supreme Court Restores Access to Abortion Pills—for NowBy Emily MullinScienceDrug Shortages Aren’t New. The Tripledemic Just Made You LookBy Maryn McKennaScienceA Lab-Grown-Meat Startup Gets the FDA’s Stamp of ApprovalBy Matt ReynoldsCultureAmerica’s Adderall Shortage Could Kill PeopleBy Kate KnibbsScienceWhen Will the Pandemic Truly Be ‘Over’?By Maryn McKennaBusinessJuul Will Pay $438.5M for Its Role in Underage VapingBy Beth Mole, Ars TechnicaMore Stories
.jpg)
.jpg)
